Search results
Results from the WOW.Com Content Network
This is an accepted version of this page This is the latest accepted revision, reviewed on 1 February 2025. Class of vaccines against human papillomavirus Pharmaceutical compound HPV vaccine Vaccine description Target Human papillomavirus (HPV) Vaccine type Protein subunit Clinical data Trade names Gardasil, others AHFS / Drugs.com Monograph MedlinePlus a615028 License data US DailyMed: Human ...
Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV). Cervarix is designed to prevent infection from HPV types 16 and 18, that cause about 70% of cervical cancer cases. [6] These types also cause most HPV-induced genital and head and neck cancers.
Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). [10] [7] [8] [9] [11] It was developed by Merck & Co. [12] High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. [13]
Consequently, the lower dose of 57.6 Gy was recommended. [117] [118] Because the authors used a fractionation scheme of 1.8 Gy per treatment, this dosage was not widely adopted, practitioners preferring a larger fraction of 2 Gy to produce a shorter treatment time, and a slightly higher dose of 60 Gy in 2 Gy fractions (30 daily treatments). [41]
An HPV infection is caused by the human papillomavirus, a DNA virus from the papillomavirus family. [8] [9] Over 200 types have been described. [10] An individual can become infected with more than one type of HPV, [11] and the disease is only known to affect humans.
Inosine pranobex may be prescribed for the treatment of HPV infections both benign and oncogenic, [24] as a very safe and effective alternative therapy. Usually it is administered in combination with other treatment methods, such as CO 2 laser and podophyllotoxin .
Human papillomavirus (HPV) infection is a cause of nearly all cases of cervical cancer. [6] Most women will successfully clear HPV infections within 18 months. Those that have a prolonged infection with a high-risk type (e.g. types 16, 18, 31, 45) are more likely to develop Cervical Intraepithelial Neoplasia , due to the effects that HPV has on ...
Laryngeal papillomatosis is caused by human papillomavirus (HPV) infection, most frequently types 6 and 11, [13] although genotypes 16, 18, 31, and 33 have also been implicated. [7] HPV-11 is associated with more aggressive forms of papillomatosis, which may involve more distal parts of the tracheobronchial tree. [ 7 ]